Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Prepares For U.S. Statin Market Shake-Up As Lipitor Goes Generic

This article was originally published in The Pink Sheet Daily

Executive Summary

Pricing pressure on AstraZeneca's Crestor expected from the arrival of generic atorvastatin in the U.S. in the fourth quarter.

You may also be interested in...

Today’s Statin Debate Bears Lessons For Tomorrow’s Cholesterol Drugs

Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.

Will New Injectables Sell In An Oral, Mainly Generic Cholesterol World?

PCSK9 inhibitors have come into vogue based on potent LDL-lowering in early studies. But the up-and-coming biologics still face questions about how they will fit in a market dominated largely by proven, oral generics.

AstraZeneca To Lay Off 24% Of U.S. Sales Force As Of Feb. 2012

The company isn’t providing much detail on reasons or commercial strategy going forward, but its long-term outlook, particularly in western markets, is uninspiring, burdened by generic competition and a mixed R&D track record.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts